A $6.2 million windfall from the sale of its Tilt-C technology to GE Medical Systems helped Fischer Imaging of Denver land solidly in the black for its first quarter (end-April). The company also reported a 3.6% increase in product sales for the quarter
A $6.2 million windfall from the sale of its Tilt-C technology to GE Medical Systems helped Fischer Imaging of Denver land solidly in the black for its first quarter (end-April). The company also reported a 3.6% increase in product sales for the quarter on higher service revenue and increased mammography shipments.
Fischer posted revenues of $20.4 million, compared with sales of $13.7 million in the first quarter of 1998. Excluding the GE payment, Fischer would have posted sales of $14.2 million. Fischer in April agreed to sell manufacturing rights to Tilt-C to Milwaukee-based GE (SCAN 4/14/99).
On the profit side, Fischer recorded net income of $3.4 million, compared with a net loss of $1.1 million in the same period a year ago. The company posted an operating loss of $1.6 million for the quarter, due in large part to costs associated with the move of its manufacturing operations from Addison, IL, to Denver.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.